Induction of Fas ligand-mediated apoptosis by interferon-α

Clinical Immunology

Volumn 95, Issue 3, 2000, Pages 218-226

  Kirou, Kyriakos A ^a   Vakkalanka, Radha Krishna ^a   Butler, Maria J ^a   Crow, Mary K ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; Cytokines; FACS; Human; NK cells

Indexed keywords

ALPHA INTERFERON; CYTOKINE; FAS ANTIGEN; FAS LIGAND; INTERLEUKIN 10; MESSENGER RNA; MONOCLONAL ANTIBODY;

APOPTOSIS; ARTICLE; CELL CYCLE; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE ACTIVATED CELL SORTER; HUMAN; HUMAN CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; T LYMPHOCYTE SUBPOPULATION; VIRUS CELL INTERACTION;

EID: 0344002720     PISSN: 15216616     EISSN: None     Source Type: Journal    
DOI: 10.1006/clim.2000.4866     Document Type: Article

References (57)

1. Nagata S., Goldstein P. The Fas death factor. Science. 267:1995;1449-1456.
2. Liu C. C., Young L. H., Young J. D. Lymphocyte-mediated cytolysis and disease. N. Engl. J. Med. 335:1996;1651-1659.
3. Biron C. A., Nguyen K. B., Pien G. C., Cousens L. P., Salazar-Mather T. P. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol. 17:1999;189-220.
4. Arase H., Arase N., Saito T. Fas mediated cytotoxicity by freshly isolated natural killer cells. J. Exp. Med. 181:1995;1235-1238.
5. Lee R. K., Spielman J., Zhao D. Y., Olsen K. J., Podack E. R. Perforin, Fas ligand, and tumor necrosis factor are the major cytotoxic molecules used by lymphokine-activated killer cells. J. Immunol. 157:1996;1919-1925.
6. Zamai L., Ahmad M., Bennett I. M., Azzoni L., Alnemri E. S., Perussia B. Natural killer (NK) cell-mediated cytotoxicity: Differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 188:1998;2375-2380.
7. Latinis K. M., Carr L. L., Peterson E. J., Norian L. A., Eliason S. L., Koretzky G. A. Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. J. Immunol. 158:1997;4602-4611.
8. Debatin K. M., Fahrig-Faissner A., Enenkel-Stoodt S., Kreuz W., Benner A., Krammer P. H. High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1-infected children. Blood. 83:1994;3101-3103.
9. Falk M. H., Trauth B. C., Debatin K. M., Klas C., Gregory C. D., Rickinson A. B., Calender A., Lenoir G. M., Ellwart J. W., Krammer P. H., Bornkamm G. W. Expression of the APO-1 antigen in Burkitt lymphoma cell lines correlates with a shift towards a lymphoblastoid phenotype. Blood. 79:1992;3300-3306.
10. Medvedev A. E., Johnsen A. C., Haux J., Steinkjer B., Egeberg K., Lynch D. H., Sundan A., Espevik T. Regulation of Fas and Fas-ligand expression in NK cells by cytokines and the involvement of Fas-ligand in NK/LAK cell-mediated cytotoxicity. Cytokine. 9:1997;394-404.
11. Mori S., Jewett A., Murakami-Mori K., Cavalcanti M., Bonavida B. The participation of the Fas-mediated cytotoxic pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol. Immunother. 44:1997;282-290.
12. Bradley M., Zeytun A., Rafi-Janajreh A., Nagarkatti P. S., Nagarkatti M. Role of spontaneous and interleukin-2-induced natural killer cell activity in the cytotoxicity and rejection of Fas+ and Fas- tumor cells. Blood. 92:1998;4248-4255.
13. Xu X., Fu X. Y., Plate J., Chong A. S. IFN-γ induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for upregulation of Fas and FasL expression. Cancer Res. 58:1998;2832-2837.
14. Tsutsui H., Nakanishi K., Matsui K., Higashino H., Okamura Y., Miyazawa Y., Kaneda K. IFN-γ-inducing factor up-regulates Fas ligand-mediated cytotoxic activity of murine natural killer cell clones. J. Immunol. 157:1996;3967-3973.
15. Ye W., Young J. D., Liu C. C. Interleukin-15 induces the expression of mRNAs of cytolytic mediators and augments cytotoxic activities in primary murine lymphocytes. Cell. Immunol. 174:1996;54-62.
16. Genestier L., Kasibhatla S., Brunner T., Green D. R. Transforming growth factor beta1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J. Exp. Med. 189:1999;231-239.
17. Pfeffer L. M., Dinarello C. A., Hererman R. B., Williams B. R., Borden E. C., . Bordens R., Walter M. R., Nagabhusan T. L., Trotta P. P., Pestka S. Biologic properties of recombinant α-interferons: 40th anniversary of the discovery of the interferons. Cancer Res. 58:1998;2489-2499.
18. Bellardelli F., Gresser I. The neglected role of type I interferon in the T-cell response: Implications for its clinical use. Immunol. Today. 17:1996;369-372.
19. Gutterman J. U. Cytokine therapeutics: Lessons from interferon α Proc. Natl. Acad. Sci. USA. 91:1994;1198-1205.
20. Trinchieri G., Santoli D. Antiviral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. J. Exp. Med. 147:1978;1314-1333.
21. Herberman R. B., Ortaldo J. R., Bonnard G. D. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature. 277:1979;221-223.
22. Djeu J. Y., Stocks N., Zoon K., Stanton G. J., Timonen T., Herberman R. B. Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J. Exp. Med. 156:1982;1222-1234.
23. Orange J. S., Biron C. A. Characterization of early IL-12, IFN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J. Immunol. 156:1996;4746-4756.
24. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64:1990;2309-2318.
25. Trauth B. C., Klas C., Peters A. M. J., Matzku S., Möller P., Falk W., Debatin K.-M., Krammer P. H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science. 245:1989;301-305.
26. Hooks J. J., Moutsopoulos H. M., Geis S. A., Stahl N. I., Decker J. L., Notkins A. N. Immune interferon in the circulation of patients with autoimmune disease. N. Engl. J. Med. 301:1979;5-8.
27. Preble O. T., Black R. J., Friedman R. M., Klippel J. H., Vilcek J. Systemic lupus erythematosus: Presence in human serum of an unusual acid-labile leukocyte interferon. Science. 216:1982;429-431.
28. Llorente L., Richaud-Patin Y., Wijdenes J., Alcocer-Varela J., Maillot M. C., Durand-Gasselin I., Fourrier B. M., Galanaud P., Emilie D. Spontaneous production of interleukin-10 by B lymphocytes and monocytes in systemic lupus erythematosus. Eur. Cytokine Netw. 4:1993;421-427.
29. Georgescu L., Vakkalanka R. K., Elkon K. B., Crow M. K. Interleukin-10 promotes activation-induced cell death of SLE lymphocytes mediated by Fas ligand. J. Clin. Invest. 100:1997;2622-2633.
30. Takahashi T., Tanaka M., Inazawa J., Abe T., Suda T., Nagata S. Human Fas ligand: Gene structure, chromosomal location and species specificity. Int. Immunol. 6:1994;1567-1574.
31. + cells in SCID mice. Transplant. Proc. 25:1993;1227-1229.
32. Lindahl-Magnuson P., Leary P., Gresser I. Interferon inhibits DNA synthesis induced in mouse lymphocyte suspensions by phytohaemagglutinin or by allogeneic cells. Nat. New Biol. 237:1972;120-121.
33. Bossi G., Griffiths G. M. Degranulation plays an essential part in regulating cell surface expression of Fas ligand in T cells and natural killer cells. Nat. Med. 5:1999;90-96.
34. Kiener P. A., Davis P. M., Starling G. C., Mehlin C., Klebanoff S. J., Ledbetter J. A., Liles W. C. Differential induction of apoptosis by Fas-Fas ligand interactions in human monocytes and macrophages. J. Exp. Med. 185:1997;1511-1516.
35. Griffith T. S., Wiley S. R., Kubin M. Z., Sedger L. M., Maliszewski C. R., Fanger N. A. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J. Exp. Med. 189:1999;1343-1354.
36. Ekmekcioglu S., Okcu M. F., Colome-Grimmer M. I., Owen-Schaub L., Buzaid A. C., Grimm E. A. Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10. Melanoma Res. 9:1999;261-272.
37. Vujanovic N. L., Nagashima S., Herberman R. B., Whiteside T. L. Nonsecretory apoptotic killing by human NK cells. J. Immunol. 157:1996;1117-1126.
38. Moulin F., Raymond J., Iniguez J.-L., Ravilly S., Lebon P., Gendrel D. Serum alpha-interferon in lower respiratory tract infections of children. Pediatr. Infect. Dis. J. 15:1996;883-886.
39. Merigan T. C., Oldstone M. B. A., Welsh R. M. Interferon production during lymphocytic choriomeningitis virus infection of nude and normal mice. Nature. 268:1977;67-68.
40. Levis S. C., Saavedra M. C., Ceccoli C., Feuillade M. R., Enria D. A., Maiztegui J. I., Falcoff R. Correlation between endogenous interferon and the clinical evolution of patients with Argentine hemorrhagic fever. J. Interferon Res. 5:1985;383-389.
41. Siegal F. P., Kadowaki N., Shodell M., Fitzgerald-Bocarsly P. A., Shah K., Ho S., Antonenko S., Liu Y. J. The nature of the principal type 1 interferon-producing cells in human blood. Science. 284:1999;1835-1837.
42. Cella M., Jarrossay D., Facchetti F., Alebardi O., Nakajima H., Lanzavecchia A., Colonna M. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5:1999;919-923.
43. Eischen C. M., Schilling J. D., Lynch D. H., Krammer P. H., Leibson P. J. Fc receptor-induced expression of Fas ligand on activated NK cells facilitates cell-mediated cytotoxicity and subsequent autocrine NK cell apoptosis. J. Immunol. 156:1996;2693-2699.
44. Sarna G., Figlin R., Bryson Y., Garratty E., Myers L., Le Fevre C., Mauritzon N., Cline M. Human alpha-lymphoblastoid interferon. A phase I study including pharmacokinetics and effects on hematologic stem cells (CFU-GMs). Am. J. Clin. Oncol. 8:1985;406-412.
45. Grimley P. M., Davis G. L., Kang Y.-H., Dooley J. S., Strohmaier J., Hoofnagle J. H. Tubuloreticular inclusions in peripheral blood mononuclear cells related to systemic therapy with α-interferon. Lab. Invest. 52:1985;638-649.
46. Buechner S. A., Wernli M., Harr T., Hahn S., Itin P., Erb P. Regression of basal cell carcinoma by intralesional interferon-α treatment is mediated by CD95(Apo-1/Fas)-CD95 ligand-induced suicide. J. Clin. Invest. 100:1997;2691-2696.
47. Selleri C., Sato T., Del Vecchio L., Luciano L., Barett A. J., Rotoli B., Young N. S., Maciejewski J. P. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-α in chronic myelogenous leukemia. Blood. 89:1997;957-964.
48. Lee S. B., Esteban M. The interferon-induced double stranded RNA-activated protein kinase induces apoptosis. Virology. 199:1994;491-496.
49. Castelli J. C., Hassel B. A., Wood K. A., Li X. L., Amemiya K., Dalakas M. C., Torrence P. F., Youle R. J. A study of the interferon antiviral mechanism: Apoptosis activation by the 2-5A system. J. Exp. Med. 186:1997;967-972.
50. Tamura T., Ishihara M., Lamphier M. S., Tanaka N., Oishi I., Aizawa S., Matsuyama T., Mak T. W., Taki S., Taniguchi T. An IRF-1-dependent pathway of DNA damage-induced apoptosis in mitogen activated T lymphocytes. Nature. 376:1995;596-599.
51. Mamane Y., Heylbroeck C., Genin P., Algarte M., Servant M. J., LePage C., DeLuca C., Kwon H., Lin R., Hiscott J. Interferon regulatory factors: The next generation. Gene. 237:1999;1-14.
52. Kalkner K. M., Ronnblom L., Karlsson Parra A. K., Bengtsson M., Olsson Y., Oberg. K. Antibodies against double-stranded DNA and development of polymyositis during treatment with interferon. Q. J. Med. 91:1998;393-399.
53. Ronnblom L. E., Alm G. V., Oberg K. E. Possible induction of systemic lupus erythematosus by interferon-α treatment in a patient with a malignant carcinoid tumor. J. Intern. Med. 227:1990;207-210.
54. Schilling P. J., Kurzrock R., Kantarjian H., Gutterman J. U., Talpaz M. Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia. Cancer. 68:1991;1536-1537.
55. Bell D. A., Morrison B. The spontaneous apoptotic cell death of normal human lymphocytes in vitro: The release of, and immunoproliferative response to, nucleosomes in vitro. Clin. Immunol. Immunopathol. 60:1991;13-26.
56. Casciola-Rosen L. A., Anhalt G., Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J. Exp. Med. 179:1994;1317-1330.
57. Luft T., Pang K. C., Thomas E., Hertzog P., Hart D. N., Trapani J., Cebon J. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161:1998;1947-1953.